News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Non-alcoholic fatty liver disease is very common, in which subgroup does cancer develop more frequently – Osman Sütcüoğlu
Photo of Osman Sütcüoğlu from kirsehireah.saglik.gov.tr
Jul 8, 2023, 11:30

Non-alcoholic fatty liver disease is very common, in which subgroup does cancer develop more frequently – Osman Sütcüoğlu

Non-alcoholic fatty liver disease is very common, in which subgroup does cancer develop more frequently?  

The incidence of HCC development is increasing in patients with type 2 diabetes.

A must-read article! – Click here

Source: Osman Sütcüoğlu/Twitter

cancer Non-alcoholic fatty liver OncoDaily Oncology Osman Sütcüoğlu type 2 diabetes
Special Coverage
Blog
Mar 22, 2025, 09:58
One story can change medical practice - EGFR Positive Lung Cancer UK
Science
Mar 22, 2025, 09:11
Myeloma Paper of the Day, March 22nd, suggested by Robert Orlowski
Blog
Mar 22, 2025, 09:00
Andrea Anampa-Guzmán: Fantastic time at the ASCO AIOM Clinical Research Course
Blog
Mar 22, 2025, 08:43
Richard Sassun: It is time to give Tumor Deposit a proper role in the staging
Blog
Mar 22, 2025, 08:34
Registration open for the 8th "Combinations and Sequences in therapy" conference
Blog
Mar 22, 2025, 08:02
AstraZeneca announced plans to establish a new global strategic Research and Development center in Beijing
Science
Mar 22, 2025, 07:56
Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors - The Babak Lab
Blog
Mar 22, 2025, 07:49
UICC joined the Commonwealth Secretariat and the Lancet Oncology Commission in London
Blog
Mar 22, 2025, 07:42
President of Cairo University visited the Breast Cancer Hospital (NCI - New Cairo)
Blog
Mar 22, 2025, 07:31
Istvan Petak: We have officially launched BRECISE in Madrid
Science
Mar 22, 2025, 07:26
Elvina Almuradova: Cemiplimab monotherapy vs chemotherapy as a first-line treatment with advanced NSCLC with PD-L1 expression
Blog
Mar 22, 2025, 07:23
Reducing disparities in cancer prevention, screening, and access to treatment - SPCC